Evaluation of [68Ga]Ga-PSMA PET/CT images acquired with a reduced scan time duration in prostate cancer patients using the digital biograph vision
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2191-219X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Evaluation of [68Ga]Ga-PSMA PET/CT images acquired with a reduced scan time duration in prostate cancer patients using the digital biograph vision ; volume:11 ; number:1 ; day:28 ; month:2 ; year:2021 ; pages:1-12 ; date:12.2021
EJNMMI Research ; 11, Heft 1 (28.2.2021), 1-12, 12.2021
- Urheber
-
Weber, Manuel
Jentzen, Walter
Hofferber, Regina
Herrmann, Ken
Fendler, Wolfgang Peter
Conti, Maurizio
Wetter, Axel
Kersting, David
Rischpler, Christoph
Fragoso Costa, Pedro
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13550-021-00765-y
- URN
-
urn:nbn:de:101:1-2021041512093407671636
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:48 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Weber, Manuel
- Jentzen, Walter
- Hofferber, Regina
- Herrmann, Ken
- Fendler, Wolfgang Peter
- Conti, Maurizio
- Wetter, Axel
- Kersting, David
- Rischpler, Christoph
- Fragoso Costa, Pedro
- SpringerLink (Online service)
Ähnliche Objekte (12)
Ressourceneffizienz durch Produktionsplanung und Lean Production
Neuartiges Antriebskonzept zum Fahren, Lenken und Heben
Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from 68Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficient
Evaluation of 18F-FDG PET/CT images acquired with a reduced scan time duration in lymphoma patients using the digital biograph vision
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis
Action-based quantum Monte Carlo approach to fermion-boson models
Assoziation zwischen molekularpathologischen Alterationen beim papillären Schilddrüsenkarzinom und dem Auftreten einer radiojodrefraktären Erkrankung
Changes in tumor-to-blood ratio as a prognostic marker for progression-free survival and overall survival in neuroendocrine tumor patients undergoing PRRT
Just another “Clever Hans”? Neural networks and FDG PET-CT to predict the outcome of patients with breast cancer
2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke
Recurrent prostate cancer: combined role for MRI and PSMA-PET in 68Ga-PSMA-11 PET/MRI
The novel PROMISE framework for PSMA-PET reporting: ready for the clinical routine?
Ressourceneffizienz durch Produktionsplanung und Lean Production
Neuartiges Antriebskonzept zum Fahren, Lenken und Heben
Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from 68Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficient
Evaluation of 18F-FDG PET/CT images acquired with a reduced scan time duration in lymphoma patients using the digital biograph vision
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis
Action-based quantum Monte Carlo approach to fermion-boson models
Assoziation zwischen molekularpathologischen Alterationen beim papillären Schilddrüsenkarzinom und dem Auftreten einer radiojodrefraktären Erkrankung
Changes in tumor-to-blood ratio as a prognostic marker for progression-free survival and overall survival in neuroendocrine tumor patients undergoing PRRT
Just another “Clever Hans”? Neural networks and FDG PET-CT to predict the outcome of patients with breast cancer
2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke
Recurrent prostate cancer: combined role for MRI and PSMA-PET in 68Ga-PSMA-11 PET/MRI
The novel PROMISE framework for PSMA-PET reporting: ready for the clinical routine?
Ressourceneffizienz durch Produktionsplanung und Lean Production
Neuartiges Antriebskonzept zum Fahren, Lenken und Heben
Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from 68Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficient
Evaluation of 18F-FDG PET/CT images acquired with a reduced scan time duration in lymphoma patients using the digital biograph vision
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis
Action-based quantum Monte Carlo approach to fermion-boson models
Assoziation zwischen molekularpathologischen Alterationen beim papillären Schilddrüsenkarzinom und dem Auftreten einer radiojodrefraktären Erkrankung
Changes in tumor-to-blood ratio as a prognostic marker for progression-free survival and overall survival in neuroendocrine tumor patients undergoing PRRT
Just another “Clever Hans”? Neural networks and FDG PET-CT to predict the outcome of patients with breast cancer
2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke
Recurrent prostate cancer: combined role for MRI and PSMA-PET in 68Ga-PSMA-11 PET/MRI